Johnny Stilou, Scandion Oncology acting CEO
October 3, 2022 08:42 AM EDTUpdated 11:27 AM
R&D

Scan­dion's shares fall af­ter on­col­o­gy biotech re­ports PhII fail

Paul Schloesser

Associate Editor

Dan­ish biotech Scan­dion On­col­o­gy post­ed some Phase II re­sults on Fri­day, and in­vestors were none too pleased.

The biotech re­port­ed topline re­sults from the sec­ond …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Viking CEO on ‘shock­ing’ mar­ket re­ac­tion to oral obe­si­ty da­ta, prepar­ing for Phase 3

Ver­tex makes mon­ey from sick­le cell ther­a­py Cas­gevy

Sana nar­rows fo­cus again to ze­ro in on di­a­betes and au­toim­mune dis­ease

Beam dis­clos­es first clin­i­cal da­ta on base-edit­ed sick­le cell ther­a­py, one pa­tient death

The elec­tion is Tues­day. What’s at stake for the phar­ma in­dus­try?

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times